Andere talen eFFECTOR Therapeutics, Inc.

Aandelen

EFTR

US28202V2079

Geschatte realtime Cboe BZX Andere beurzen 18:36:21 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,825 ^USD	-5,93%		-3,70%	-84,42%

04/04	Top Middag Decliners	MT
04/04	EFFECTOR Therapeutics, Inc. Kondigt topresultaten aan van de Fase 2 KICKSTART-studie met tomivosertib in combinatie met pembrolizumab bij niet-kleincellige longkanker	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Health Care Down on Retreat From Risk -- Health Care Roundup	04/04
Top Midday Decliners	04/04
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04
Top Premarket Decliners	26/03
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	25/03
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	05/02
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	25/01
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01
EFFECTOR Therapeutics Announces Reverse Stock Split	09/01
EFFECTOR Therapeutics Announces Reverse Stock Split	09/01
EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS	11/12
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data	08/12
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer	28/11
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer	28/11
The role of STRIs in cancer	27/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen eFFECTOR Therapeutics, Inc.

Aandelen

EFTR

US28202V2079

Andere talen

Filters